Trial Profile
Randomized open label controlled trial to study Safety and Effect of itolizumab (antiCD6) in Relapsing Remitting Multiple Sclerosis.
Status:
Planning
Phase of Trial:
Phase I/II
Latest Information Update: 14 Oct 2020
Price :
$35
*
At a glance
- Drugs Itolizumab (Primary) ; Interferon beta-1a
- Indications Multiple sclerosis
- Focus Adverse reactions
- 29 Aug 2016 New trial record